Regeneron says allergy drug may be darling of its pipeline

September 19, 2014 7:32 PM

16 0

(Reuters) - Regeneron Pharmaceuticals Inc has quickly become one of the world's biggest biotech companies thanks to its Eylea treatment for macular degeneration, but its little known experimental allergy drug could become equally successful, senior company executives said in interviews.

The allergy drug, dupilumab, is meant to treat underlying causes of asthma, eczema and nasal polyps and could transform treatment of those suspected related ailments, the officials say.

Also read: Experimental Ebola Treatment May Be Deployed to Congo

Read more

To category page